Teva Pharmaceutical (TEVA) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Teva Pharmaceutical (TEVA)

34.43

-0.03 (0.09%)

as of Aug 4, 2026, 8:00:00 pm Market Open.

70 watching

Investor Insights

Aug 4, 2026, 12:00 am

This summary was created by AI, based on 4 opinions in the last 12 months.

Teva Pharmaceutical (TEVA-N) has garnered mixed reviews from various experts, reflecting a dynamic yet cautious outlook on its performance. In recent months, the stock has significantly appreciated, showing a 264% increase since early 2023 under the leadership of its current CEO. Despite this positive trajectory, experts express concerns regarding the erosion of prices in the GLP market as more generics come into play, which could impact Teva's profitability. While it has exhibited strong momentum and accumulated growth since breaking the $21 mark in September, there's skepticism about its level of innovation in an increasingly competitive pharmaceutical landscape. Analysts project a bullish target price of $34.50, underlining potential optimism despite the caveats presented in the commentary.

Consensus

Mixed

Valuation

Fair Value

Similar

Novartis, NVS

PAST TOP PICK

(A Top Pick Jan 9/07. Up 45,7%.) World’s largest generic drug manufacturer. Has been a major beneficiary of the majors losing patents. Still buying.

Wealthica Track your Stocks in your Watch List

TOP PICK

A long time favourite. It is the largest generic pharmaceutical company. They will be able to benefit from the aging population and government wanting more generic prescriptions. He bought this stock in the low 30's.

BUY

The best company to own in the generics drug area.

TOP PICK

Sitting by its all-time high even in this poor market. Largest generic drug manufacturer in the world. A major beneficiary of an economic slowdown because people will switch from branded products to generics. Major beneficiary of drugs coming off patent.

PAST TOP PICK

(A Top Pick July 25/06. Up 42%.) Still a Buy. The biggest generic drug manufacturer in the world.

BUY

An Israeli generics pharmaceutical company. At these levels, it is a very interesting stock.

TOP PICK

World's largest generic drug manufacturer. Has gone from being a growth stock to a value stock. A lot more patented drugs will be coming off in 2007 and 2008.

BUY

World’s largest generic drug manufacturer. Also have their own branded drug division. Made some acquisitions and is going through some digestion, but a year from now the stock should be significantly higher.

BUY

Generic pharmaceutical company. Very well run. Lots of cash.

BUY

World’s largest generic drug manufacturer. A value stock. Has a great pipeline of new drugs coming out in the next few years, both generic and its own proprietary drugs. Pfizer’s (PFE-N) Lipitor drug does not come off patent until 2011.

BUY

World’s largest generic drug manufacturer with most sales in North America. Reported great earnings, but stock has acted poorly lately because next year’s growth is not going to be as big. Good price.

BUY

Generic drugs. Trades and about 16 X earnings. Has a lot of cash on its balance sheet. There is a lot of competition in the generic sector still expects there will be mergers. It should continue to do well.

TOP PICK

World's largest generic drug manufacturer. Gone from being a growth stock to a value stock. Merck and Pfizer have come out with their own generics when their drugs came off patent. Based in Israel. The drop in price gives a good opportunity.

BUY

Largest generic drug manufacturer in the world. Likes long-term outlook for generics. Emerging markets have come off which affected the stock. Bit of a tumult on drugs coming off patent with original patent owners issuing drugs for less than generics. A temporary phenomena and this company will again be on top.

WAIT

In the top 2 of the world's generic drug manufacturers. Interesting dynamics going on in the healthcare sector. When the patent came off Zocor, Merck (MRK-N) lowered their price below the generic price. This was a first but other companies could follow this tactic so, he is staying on the sidelines. Recently sold his holdings.

Showing 226 to 240 of 276 entries

Most Recent Experts

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Jim Cramer - Mad Money

CNBC

The Monthly Gems by Allan Tong

Stockchase

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Teva Pharmaceutical (TEVA)